The technology developed by Polytheragene finds its origin in some research carried out in two laboratories, one laboratory belonging to the university of Evry Val d’Essonne, and a laboratory of the French National Research Council (CNRS) at Orleans, working on the domain of the synthetic vectors for nucleic acid transfer (DNA and RNA), and hydrophobic therapeutics delivery.
Polytheragene is developing two new families of synthetic vectors. The first family comprised PTG1 and PTG3 for bioproduction of proteins and viruses. PTG1 is a polymer very efficient for DNA transfection while PTG3 is an other polymer efficient for DNA and mRNA transfection. The second family is PTG2 comprising triblock copolymers having very high capacity to solubilize and vectorize very hydrophobic therapeutically active molecules.
Polymeric molecules developed by Polytheragene are of low in vitro and in vivo toxicity. Upon request, they can be functionalized by fluorescent or spectroscopically active functions and/or by tags for targeting. PTG2 products can be adapted to vectorization of various hydrophobic molecules and favor their biodistribution. Functionalization is also possible.